Real-World Evidence on Second-Line Therapy Selection and Outcomes


Medical experts discuss how the time to progression, progression patterns, and real-world data influence the provider's choice of treatment for patients with hepatocellular carcinoma.

Related Videos
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
Video  9 - "Additional Second-Line Treatments for HCC"
Video 16 - "Neoadjuvant Approach in RAI-R-DTC"
Video 15 - "Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment"
A panel of 4 experts on colorectal cancer
Video 8 - "The Evolving Landscape of Second-Line Therapies in HCC Management"
Video 7 - "Comorbidity Considerations for HCC Treatment"
Video 8 - "Future Outlook for RET Fusion-Targeted Therapies"
Video 7 - "Impact and Positioning of Tumor Agnostic Approvals"
Related Content